| 25.9 -0.82 (-3.07%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.36 |
1-year : | 32.7 |
| Resists | First : | 26.85 |
Second : | 28 |
| Pivot price | 26.29  |
|||
| Supports | First : | 25 |
Second : | 20.8 |
| MAs | MA(5) : | 26.54 |
MA(20) : | 26.19 |
| MA(100) : | 25.05 |
MA(250) : | 30.24 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 61.5 |
D(3) : | 68.7 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 40.47 | Low : | 14.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CGON ] has closed above bottom band by 28.4%. Bollinger Bands are 71.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.57 - 26.75 | 26.75 - 26.9 |
| Low: | 25.25 - 25.42 | 25.42 - 25.56 |
| Close: | 25.65 - 25.93 | 25.93 - 26.16 |
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Sat, 26 Apr 2025
CG Oncology Bladder Cancer Drug Shows 42% Complete Response at 24 Months | CGON Stock News - Stock Titan
Thu, 24 Apr 2025
CG Oncology's Breakthrough Phase 3 Bladder Cancer Treatment Data: What The AUA Plenary Will Reveal - Stock Titan
Wed, 02 Apr 2025
CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (NASDAQ:CGON) - Seeking Alpha
Fri, 28 Mar 2025
CG Oncology, Inc. SEC 10-K Report - TradingView
Tue, 21 Jan 2025
This CG Oncology Insider Reduced Their Stake By 16% - simplywall.st
Mon, 16 Dec 2024
CG Oncology Closes $238 Million Public Offering of Common Stock - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 6.113e+007 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 11,560 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3435e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -81 % |
| Return on Assets (ttm) | 161.5 % |
| Return on Equity (ttm) | -12.9 % |
| Qtrly Rev. Growth | 662000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -82 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.108e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|